{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:58:57Z","timestamp":1778680737977,"version":"3.51.4"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,2,18]],"date-time":"2016-02-18T00:00:00Z","timestamp":1455753600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s40259-016-0162-9","type":"journal-article","created":{"date-parts":[[2016,2,18]],"date-time":"2016-02-18T20:36:18Z","timestamp":1455827778000},"page":"75-86","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":185,"title":["Trastuzumab in the Treatment of Breast Cancer"],"prefix":"10.1007","volume":"30","author":[{"given":"Sofia","family":"Maximiano","sequence":"first","affiliation":[]},{"given":"Paulo","family":"Magalh\u00e3es","sequence":"additional","affiliation":[]},{"given":"Mara Pereira","family":"Guerreiro","sequence":"additional","affiliation":[]},{"given":"Manuel","family":"Morgado","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,2,18]]},"reference":[{"key":"162_CR1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2217\/fon.12.61","volume":"8","author":"JR Benson","year":"2012","unstructured":"Benson JR, Jatoi I. The global breast cancer burden. Future Oncol. 2012;8:697\u2013702.","journal-title":"Future Oncol."},{"key":"162_CR2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.canep.2009.10.003","volume":"33","author":"S Coughlin","year":"2009","unstructured":"Coughlin S, Ekwueme D. Breast cancer as a global health concern. Cancer Epidemiol. 2009;33:315\u20138.","journal-title":"Cancer Epidemiol."},{"key":"162_CR3","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.ejca.2014.03.016","volume":"50","author":"M Corbex","year":"2014","unstructured":"Corbex M, Bouzbid S, Boffetta P. Features of breast cancer in developing countries, examples from North-Africa. Eur J Cancer. 2014;50:1808\u201318.","journal-title":"Eur J Cancer"},{"key":"162_CR4","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s13277-013-0759-2","volume":"34","author":"MJ Duffy","year":"2013","unstructured":"Duffy MJ. The war on cancer: are we winning? Tumour Biol. 2013;34:1275\u201384.","journal-title":"Tumour Biol"},{"key":"162_CR5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.7150\/jca.4925","volume":"4","author":"G Tinoco","year":"2013","unstructured":"Tinoco G, Warsch S, Gl\u00fcck S, Avancha K, Montero AJ. Treating breast cancer in the 21st century: emerging biological therapies. J Cancer. 2013;4:117\u201332.","journal-title":"J Cancer."},{"key":"162_CR6","first-page":"24","volume":"81","author":"L Lambert","year":"2014","unstructured":"Lambert L. Biological drugs in breast cancer: increasing understanding for the pharmacist. S Afr Pharm J. 2014;81:24\u20137.","journal-title":"S Afr Pharm J."},{"key":"162_CR7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/11204680-000000000-00000","volume":"24","author":"KP Garnock-Jones","year":"2010","unstructured":"Garnock-Jones KP, Keating GM, Scott LJ. Spotlight on trastuzumab as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. BioDrugs. 2010;24:207\u20139.","journal-title":"BioDrugs."},{"key":"162_CR8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.suronc.2008.11.001","volume":"19","author":"N Patani","year":"2010","unstructured":"Patani N, Mokbel K. Herceptin and breast cancer: an overview for surgeons. Surg Oncol. 2010;19:11\u201321.","journal-title":"Surg Oncol"},{"key":"162_CR9","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2165\/00019053-200826080-00006","volume":"26","author":"K McKeage","year":"2008","unstructured":"McKeage K, Lyseng-Williamson KA. Trastuzumab: a pharmacoeconomic review of its use in early breast cancer. Pharmacoeconomics. 2008;26:699\u2013719.","journal-title":"Pharmacoeconomics."},{"key":"162_CR10","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1016\/j.breast.2013.07.029","volume":"22","author":"AC Pinto","year":"2013","unstructured":"Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies. Breast. 2013;22:S152\u20135.","journal-title":"Breast."},{"key":"162_CR11","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1093\/annonc\/mdt217","volume":"24","author":"WJ Gradishar","year":"2013","unstructured":"Gradishar WJ. Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. Ann Oncol. 2013;24:2492\u2013500.","journal-title":"Ann Oncol"},{"key":"162_CR12","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273\u201383.","journal-title":"N Engl J Med"},{"key":"162_CR13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1756-8722-6-38","volume":"6","author":"JA Incorvati","year":"2013","unstructured":"Incorvati JA, Shah S, Mu Y, Lu J. Targeted therapy for HER2 positive breast cancer. J Hematol Oncol. 2013;6:38.","journal-title":"J Hematol Oncol."},{"key":"162_CR14","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ctrv.2013.02.006","volume":"39","author":"P De","year":"2013","unstructured":"De P, Hasmann M, Leyland-Jones B. Molecular determinants of trastuzumab efficacy: what is their clinical relevance? Cancer Treat Rev. 2013;39:925\u201334.","journal-title":"Cancer Treat Rev"},{"key":"162_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/annonc\/mdu385","volume":"25","author":"F Cardoso","year":"2014","unstructured":"Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andr\u00e9 F, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol. 2014;25:1\u201318.","journal-title":"Ann Oncol"},{"issue":"Suppl 6","key":"162_CR16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/annonc\/mdt284","volume":"24","author":"E Senkus","year":"2013","unstructured":"Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):7\u201323.","journal-title":"Ann Oncol"},{"key":"162_CR17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/annonc\/mdv298","volume":"26","author":"E Senkus","year":"2015","unstructured":"Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:8\u201330.","journal-title":"Ann Oncol"},{"key":"162_CR18","first-page":"62","volume":"2","author":"T Vu","year":"2012","unstructured":"Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol. 2012;2:62.","journal-title":"Front Oncol."},{"issue":"Suppl 1","key":"162_CR19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.critrevonc.2010.09.002","volume":"84","author":"A Emde","year":"2012","unstructured":"Emde A, K\u00f6stler WJ, Yarden Y. Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. Crit Rev Oncol Hematol. 2012;84(Suppl 1):49\u201357.","journal-title":"Crit Rev Oncol Hematol"},{"key":"162_CR20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2165\/00063030-200721020-00001","volume":"21","author":"R Bartsch","year":"2007","unstructured":"Bartsch R, Wenzel C, Zielinski CC, Steger GG. HER-2-positive breast cancer: hope beyond trastuzumab. BioDrugs. 2007;21:69\u201377.","journal-title":"BioDrugs."},{"key":"162_CR21","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1158\/0008-5472.CAN-13-0687","volume":"73","author":"BN Rexer","year":"2013","unstructured":"Rexer BN, Arteaga CL. Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications. Cancer Res. 2013;73:3817\u201320.","journal-title":"Cancer Res"},{"key":"162_CR22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","volume":"94","author":"L Arnould","year":"2006","unstructured":"Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006;94:259\u201367.","journal-title":"Br J Cancer"},{"key":"162_CR23","unstructured":"European Medicines Agency. Summary of product characteristics: Herceptin. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000278\/WC500074922.pdf . Accessed 9 Feb 2016."},{"key":"162_CR24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1177\/1078155214538085","volume":"21","author":"J-R Azanza","year":"2015","unstructured":"Azanza J-R, S\u00e1daba B, G\u00f3mez-Guiu A. Monoclonal antibodies: pharmacokinetics as a basis for new dosage regimens? J Oncol Pharm Pract. 2015;21:370\u20136.","journal-title":"J Oncol Pharm Pract."},{"key":"162_CR25","first-page":"1579","volume":"34","author":"D Leveque","year":"2014","unstructured":"Leveque D. Subcutaneous administration of anticancer agents. Anticancer Res. 2014;34:1579\u201386.","journal-title":"Anticancer Res"},{"key":"162_CR26","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/0091270012436560","volume":"53","author":"C Wynne","year":"2013","unstructured":"Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B. Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I\/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol. 2013;53:192\u2013201.","journal-title":"J Clin Pharmacol"},{"key":"162_CR27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/00063030-200620040-00007","volume":"20","author":"GL Plosker","year":"2006","unstructured":"Plosker GL, Keam SJ. Spotlight on trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer. BioDrugs. 2006;20:259\u201362.","journal-title":"BioDrugs."},{"key":"162_CR28","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","volume":"13","author":"G Ismael","year":"2012","unstructured":"Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim S-B, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I\u2013III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012;13:869\u201378.","journal-title":"Lancet Oncol."},{"key":"162_CR29","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","volume":"14","author":"X Pivot","year":"2013","unstructured":"Pivot X, Gligorov J, M\u00fcller V, Barrett-Lee P, Verma S, Knoop A, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14:962\u201370.","journal-title":"Lancet Oncol."},{"key":"162_CR30","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/annonc\/mdu364","volume":"25","author":"X Pivot","year":"2014","unstructured":"Pivot X, Gligorov J, Muller V, Curigliano G, Knoop A, Verma S, et al. Patients\u2019 preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol. 2014;25:1979\u201387.","journal-title":"Ann Oncol"},{"key":"162_CR31","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1055\/s-0034-1368173","volume":"74","author":"C Jackisch","year":"2014","unstructured":"Jackisch C, M\u00fcller V, Maintz C, Hell S, Ataseven B. Subcutaneous administration of monoclonal antibodies in oncology. Geburtshilfe Frauenheilkd. 2014;74:343\u20139.","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"162_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/psp.2013.63","volume":"3","author":"F Hourcade-Potelleret","year":"2014","unstructured":"Hourcade-Potelleret F, Lemenuel-Diot A, McIntyre C, Brewster M, Lum B, Bittner B. Use of a population pharmacokinetic approach for the clinical development of a fixed-dose subcutaneous formulation of trastuzumab. CPT Pharmacomet Syst Pharmacol. 2014;3:1\u20139.","journal-title":"CPT Pharmacomet Syst Pharmacol."},{"key":"162_CR33","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1055\/s-0035-1546172","volume":"75","author":"C Jackisch","year":"2015","unstructured":"Jackisch C, M\u00fcller V, Dall P, Neumeister R, Park-Simon T-W, Ruf-D\u00f6rdelmann A, et al. Subcutaneous trastuzumab for HER2-positive breast cancer\u2014evidence and practical experience in 7 German centers. Geburtshilfe Frauenheilkd. 2015;75:566\u201373.","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"162_CR34","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/CEOR.S85599","volume":"7","author":"S Ryan","year":"2015","unstructured":"Ryan S, North R, Harvey V, Cox L. Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study. Clin Outcomes Res. 2015;7:423\u201330.","journal-title":"Clin Outcomes Res."},{"key":"162_CR35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/157488408783329931","volume":"3","author":"D Lev\u00eaque","year":"2008","unstructured":"Lev\u00eaque D, Gigou L, Bergerat JP. Clinical pharmacology of trastuzumab. Curr Clin Pharmacol. 2008;3:51\u20135.","journal-title":"Curr Clin Pharmacol."},{"key":"162_CR36","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00280-013-2273-z","volume":"72","author":"CJ Wynne","year":"2013","unstructured":"Wynne CJ, Ellis-Pegler RB, Waaka DS, Schwabe C, Lehle M, Heinzmann D, et al. Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males. Cancer Chemother Pharmacol. 2013;72:1079\u201387.","journal-title":"Cancer Chemother Pharmacol"},{"key":"162_CR37","first-page":"CD006243","volume":"4","author":"L Moja","year":"2012","unstructured":"Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;4:CD006243.","journal-title":"Cochrane Database Syst Rev."},{"key":"162_CR38","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.lpm.2013.01.054","volume":"42","author":"N Ismaili","year":"2013","unstructured":"Ismaili N, Elmajjaoui S, Tahri A, Benjaafar N, Errihani H, Belbaraka R. Trastuzumab in early breast cancer. Presse Med. 2013;42:1069\u201380.","journal-title":"Presse Med"},{"key":"162_CR39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s12032-011-9897-9","volume":"29","author":"F Petrelli","year":"2012","unstructured":"Petrelli F, Barni S. Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better. Med Oncol. 2012;29:503\u201310.","journal-title":"Med Oncol"},{"key":"162_CR40","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s12032-014-0340-x","volume":"31","author":"F Du","year":"2014","unstructured":"Du F, Yuan P, Zhu W, Wang J, Ma F, Fan Y, et al. Is it safe to give anthracyclines concurrently with trastuzumab in neo-adjuvant or metastatic settings for HER2-positive breast cancer? A meta-analysis of randomized controlled trials. Med Oncol. 2014;31:340.","journal-title":"Med Oncol"},{"key":"162_CR41","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12094-013-1084-3","volume":"15","author":"S Barco Del","year":"2013","unstructured":"Del Barco S, Ciruelos E, Tusquets I, Ruiz M, Barnadas A, SEOM. SEOM clinical guidelines for the systemic treatment of early breast cancer 2013. Clin Transl Oncol. 2013;15:1011\u20137.","journal-title":"Clin Transl Oncol"},{"key":"162_CR42","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.breast.2012.03.003","volume":"21","author":"F Cardoso","year":"2012","unstructured":"Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, et al. 1st International consensus guidelines for advanced breast cancer (ABC\u00a01). Breast. 2012;21:242\u201352.","journal-title":"Breast."},{"key":"162_CR43","unstructured":"Food and Drug Administration. Herceptin (Trastuzumab) Label. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103792s5250lbl.pdf . Accessed 9 Feb 2016."},{"key":"162_CR44","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1200\/JCO.2011.39.2613","volume":"30","author":"P Cortazar","year":"2012","unstructured":"Cortazar P, Justice R, Johnson J, Sridhara R, Keegan P, Pazdur R. US Food and Drug Administration approval overview in metastatic breast cancer. J Clin Oncol. 2012;30:1705\u201311.","journal-title":"J Clin Oncol"},{"key":"162_CR45","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","volume":"29","author":"EA Perez","year":"2011","unstructured":"Perez EA, Romond EH, Suman VJ, Jeong J-H, Davidson NE, Geyer CE, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29:3366\u201373.","journal-title":"J Clin Oncol"},{"key":"162_CR46","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","volume":"32","author":"EA Perez","year":"2014","unstructured":"Perez EA, Romond EH, Suman VJ, Jeong J-H, Sledge G, Geyer CE, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32:3744\u201352.","journal-title":"J Clin Oncol"},{"key":"162_CR47","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"L Gianni","year":"2010","unstructured":"Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER. Lancet. 2010;375:377\u201384.","journal-title":"Lancet"},{"key":"162_CR48","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(13)70502-3","volume":"14","author":"AU Buzdar","year":"2013","unstructured":"Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a random. Lancet Oncol. 2013;14:1317\u201325.","journal-title":"Lancet Oncol."},{"issue":"Suppl","key":"162_CR49","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1200\/jco.2013.31.15_suppl.526","volume":"31","author":"M Ewer","year":"2013","unstructured":"Ewer M, Suman VJ, Buzdar A, McCall LM, Meric-Bernstam F, et al. ACOSOG Z1041 (Alliance): cardiac events (CE) among those receiving neoadjuvant antracyclines (A) and taxanes with trastuzumab (T) for HER2+ breast cancer [abstract]. J Clin Oncol. 2013;31(Suppl):526.","journal-title":"J Clin Oncol"},{"key":"162_CR50","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1470-2045(13)70225-0","volume":"14","author":"X Pivot","year":"2013","unstructured":"Pivot X, Romieu G, Debled M, Pierga J-Y, Kerbrat P, Bachelot T, et al. 6\u00a0months versus 12\u00a0months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013;14:741\u20138.","journal-title":"Lancet Oncol."},{"key":"162_CR51","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/annonc\/mdv213","volume":"26","author":"D Mavroudis","year":"2015","unstructured":"Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, et al. Six versus 12\u00a0months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol. 2015;26:1333\u201340.","journal-title":"Ann Oncol"},{"key":"162_CR52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ctrv.2013.04.002","volume":"40","author":"J Albanell","year":"2014","unstructured":"Albanell J, Ciruelos EM, Lluch A, Mu\u00f1oz M, Rodr\u00edguez CA. Trastuzumab in small tumours and in elderly women. Cancer Treat Rev. 2014;40:41\u20137.","journal-title":"Cancer Treat Rev."},{"key":"162_CR53","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1007\/s12094-015-1316-9","volume":"17","author":"S Antol\u00edn-Novoa","year":"2015","unstructured":"Antol\u00edn-Novoa S, Blanco-Campanario E, Ant\u00f3n A, Gallegos-Sancho MI, P\u00e9rez-Carri\u00f3n R, Pel\u00e1ez I, et al. Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice. Clin Transl Oncol. 2015;17:862\u20139.","journal-title":"Clin Transl Oncol"},{"key":"162_CR54","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1200\/JCO.2015.60.8620","volume":"33","author":"CC O\u2019Sullivan","year":"2015","unstructured":"O\u2019Sullivan CC, Bradbury I, Campbell C, Spielmann M, Perez EA, Joensuu H, et al. Efficacy of adjuvant trastuzumab for patients with human epidermal growth factor receptor 2-positive early breast cancer and tumors \u22642\u00a0cm: a meta-analysis of the randomized trastuzumab trials. J Clin Oncol. 2015;33:2600\u20138.","journal-title":"J Clin Oncol"},{"key":"162_CR55","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1021\/jm500766w","volume":"57","author":"JM Lambert","year":"2014","unstructured":"Lambert JM, Chari RVJ. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem. 2014;57:6949\u201364.","journal-title":"J Med Chem"},{"key":"162_CR56","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40265-013-0050-2","volume":"73","author":"A Ballantyne","year":"2013","unstructured":"Ballantyne A, Dhillon S. Trastuzumab emtansine: first global approval. Drugs. 2013;73:755\u201365.","journal-title":"Drugs."},{"key":"162_CR57","first-page":"81","volume":"8","author":"JJ Maly","year":"2014","unstructured":"Maly JJ, Macrae ER. Pertuzumab in combination with trastuzumab and chemotherapy in the treatment of HER2-positive metastatic breast cancer: safety, efficacy, and progression free survival. Breast Cancer. 2014;8:81\u20138.","journal-title":"Breast Cancer."},{"key":"162_CR58","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.breast.2013.09.006","volume":"23","author":"A Mehta","year":"2014","unstructured":"Mehta A, Tripathy D. Co-targeting estrogen receptor and HER2 pathways in breast cancer. Breast. 2014;23:2\u20139.","journal-title":"Breast."},{"key":"162_CR59","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1186\/1752-1947-8-417","volume":"8","author":"K Ishizuna","year":"2014","unstructured":"Ishizuna K, Ninomiya J, Ogawa T, Tsuji E. Hepatotoxicity induced by trastuzumab used for breast cancer adjuvant therapy: a case report. J Med Case Rep. 2014;8:417.","journal-title":"J Med Case Rep."},{"key":"162_CR60","first-page":"1147","volume":"34","author":"A Sandoo","year":"2014","unstructured":"Sandoo A, Kitas GD, Carmichael AR. Endothelial dysfunction as a determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer. Anticancer Res. 2014;34:1147\u201351.","journal-title":"Anticancer Res"},{"key":"162_CR61","doi-asserted-by":"crossref","first-page":"356","DOI":"10.4048\/jbc.2014.17.4.356","volume":"17","author":"P Jitawatanarat","year":"2014","unstructured":"Jitawatanarat P, Connor TLO, Kossoff EB, Levine EG, Chittawatanarat K. Breast cancer safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancer. J Breast Cancer. 2014;17:356\u201362.","journal-title":"J Breast Cancer."},{"key":"162_CR62","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.breast.2013.09.009","volume":"22","author":"R Barroso-Sousa","year":"2013","unstructured":"Barroso-Sousa R, Santana IA, Testa L, de Melo Gagliato D, Mano MS. Biological therapies in breast cancer: common toxicities and management strategies. Breast. 2013;22:1009\u201318.","journal-title":"Breast."},{"key":"162_CR63","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4048\/jbc.2014.17.4.363","volume":"17","author":"J Xue","year":"2014","unstructured":"Xue J, Jiang Z, Qi F, Lv S, Zhang S, Wang T, et al. Risk of trastuzumab-related cardiotoxicity in early breast cancer patients: a prospective observational study. J Breast Cancer. 2014;17:363\u20139.","journal-title":"J Breast Cancer."},{"key":"162_CR64","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1038\/srep04483","volume":"4","author":"S Ahmad","year":"2014","unstructured":"Ahmad S, Gupta S, Kumar R, Varshney GC, Raghava GPS. Herceptin resistance database for understanding mechanism of resistance in breast cancer patients. Sci Rep. 2014;4:4483.","journal-title":"Sci Rep."},{"key":"162_CR65","first-page":"353","volume":"1846","author":"T Vu","year":"2014","unstructured":"Vu T, Sliwkowski MX, Claret FX. Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta. 2014;1846:353\u201365.","journal-title":"Biochim Biophys Acta"},{"key":"162_CR66","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/bjc.2014.388","volume":"111","author":"JC Singh","year":"2014","unstructured":"Singh JC, Jhaveri K, Esteva FJ. HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. Br J Cancer. 2014;111:1888\u201398.","journal-title":"Br J Cancer"},{"key":"162_CR67","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-013-2525-y","volume":"139","author":"F Zagouri","year":"2013","unstructured":"Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E, et al. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Res Treat. 2013;139:13\u201322.","journal-title":"Breast Cancer Res Treat"},{"key":"162_CR68","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40263-012-0024-z","volume":"27","author":"R Bartsch","year":"2013","unstructured":"Bartsch R, Berghoff AS, Preusser M. Optimal management of brain metastases from breast cancer: issues and considerations. CNS Drugs. 2013;27:121\u201334.","journal-title":"CNS Drugs."},{"key":"162_CR69","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.canlet.2014.12.026","volume":"358","author":"A Patil","year":"2015","unstructured":"Patil A, Sherbet GV. Therapeutic approach to the management of HER2-positive breast cancer metastatic to the brain. Cancer Lett. 2015;358:93\u20139.","journal-title":"Cancer Lett"},{"key":"162_CR70","unstructured":"Bousquet G, Darrouzain F, de Bazelaire C, Ternant D, Barranger E, Winterman S, et al. Intrathecal trastuzumab halts progression of CNS metastases in breast cancer. J Clin Oncol (Epub 29 Dec 2014)."},{"key":"162_CR71","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.breast.2011.05.007","volume":"20","author":"M Mego","year":"2011","unstructured":"Mego M, Sycova-Mila Z, Obertova J, Rajec J, Liskova S, Palacka P, et al. Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis. Breast. 2011;20:478\u201380.","journal-title":"Breast."},{"key":"162_CR72","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10549-011-1417-2","volume":"127","author":"M Oliveira","year":"2011","unstructured":"Oliveira M, Braga S, Passos-Coelho JL, Fonseca R, Oliveira J. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Res Treat. 2011;127:841\u20134.","journal-title":"Breast Cancer Res Treat"},{"key":"162_CR73","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/annonc\/mdp019","volume":"20","author":"C Ferrario","year":"2009","unstructured":"Ferrario C, Davidson A, Bouganim N, Aloyz R, Panasci LC. Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann Oncol. 2009;20:792\u20135.","journal-title":"Ann Oncol"},{"key":"162_CR74","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00280-008-0859-7","volume":"63","author":"M Colozza","year":"2009","unstructured":"Colozza M, Minenza E, Gori S, Fenocchio D, Paolucci C, Aristei C, et al. Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemother Pharmacol. 2009;63:1157\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"162_CR75","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S1470-2045(06)70864-6","volume":"7","author":"C Platini","year":"2006","unstructured":"Platini C, Long J, Walter S. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol. 2006;7:778\u201380.","journal-title":"Lancet Oncol."},{"key":"162_CR76","first-page":"1373","volume":"15","author":"HJ Stemmler","year":"2006","unstructured":"Stemmler HJ, Schmitt M, Harbeck N, Willems A, Bernhard H, L\u00e4ssig D, et al. Application of intrathecal trastuzumab (Herceptin\u2122) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep. 2006;15:1373\u20137.","journal-title":"Oncol Rep"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-016-0162-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-016-0162-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-016-0162-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T18:48:09Z","timestamp":1600195689000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-016-0162-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,18]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["162"],"URL":"https:\/\/doi.org\/10.1007\/s40259-016-0162-9","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,18]]}}}